Cutting Off Progress in HIV Prevention As experts gathered at the 2026 Aids Conference in Rio de Janeiro, a stark reality emerged: despite groundbreaking innovations in HIV prevention, US foreign aid cuts are blocking access to lifesaving medications for those who need them most.
The World Health Organization's recommendation last year to prioritize expanded access to lenacapavir, an injectable version of PrEP, has been met with bureaucratic barriers and funding constraints.
The WHO's push for widespread availability of lenacapavir is both a humanitarian imperative and a sound investment in public health.